David I. Croteau

Family Medicine

3800 Eastside Hwy
Stevensville, MT 59870

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Corneal edema: an underrecognized safety risk of amantadine.

Corneal edema: an underrecognized safety risk of amantadine.

Journal: Journal of neurology

Published: March 09, 2026

Arterial hypertension: A safety risk of calcitonin gene-related peptide ligand and receptor blocker class.

Arterial hypertension: A safety risk of calcitonin gene-related peptide ligand and receptor blocker class.

Journal: Headache

Published: November 14, 2025

Severe gastrointestinal adverse reactions including perforation, ulceration, hemorrhage, and obstruction: A fumaric acid ester class new safety risk.

Severe gastrointestinal adverse reactions including perforation, ulceration, hemorrhage, and obstruction: A fumaric acid ester class new safety risk.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: February 11, 2025

Progressive multifocal leukoencephalopathy associated with sphingosine-1-phosphate receptor modulators: A large case series.

Progressive multifocal leukoencephalopathy associated with sphingosine-1-phosphate receptor modulators: A large case series.

Journal: Multiple sclerosis and related disorders

Published: September 30, 2024

Immune-mediated colitis associated with ocrelizumab: A new safety risk.

Immune-mediated colitis associated with ocrelizumab: A new safety risk.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: September 14, 2023

Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents.

Acute Hyperkinetic Movement Disorders as a Multifactorial Pharmacodynamic Drug Interaction Between Methylphenidate and Risperidone in Children and Adolescents.

Journal: Journal of clinical psychopharmacology

Published: April 30, 2022

Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.

Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.

Journal: Drug safety

Published: December 15, 2021

Expanding spectrum of opportunistic infections associated with dimethyl fumarate.

Expanding spectrum of opportunistic infections associated with dimethyl fumarate.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 10, 2020

Hypertension: A new safety risk for patients treated with erenumab.

Hypertension: A new safety risk for patients treated with erenumab.

Journal: Headache

Published: October 13, 2020

Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.

Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 15, 2020

Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death.

Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death.

Journal: Pharmacoepidemiology and drug safety

Published: September 23, 2019

Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.

Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab.

Journal: Neurology

Published: October 10, 2017

Showing 1-12 of 14

Last Updated: 09/26/2026